Correlation Between AptaBio Therapeutics and Medy Tox

Can any of the company-specific risk be diversified away by investing in both AptaBio Therapeutics and Medy Tox at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AptaBio Therapeutics and Medy Tox into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AptaBio Therapeutics and Medy Tox, you can compare the effects of market volatilities on AptaBio Therapeutics and Medy Tox and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AptaBio Therapeutics with a short position of Medy Tox. Check out your portfolio center. Please also check ongoing floating volatility patterns of AptaBio Therapeutics and Medy Tox.

Diversification Opportunities for AptaBio Therapeutics and Medy Tox

0.76

Correlation Coefficient

AptaBio Therapeutics  Medy Tox

Poor diversification

The 3 months correlation between AptaBio and Medy is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding AptaBio Therapeutics and Medy Tox in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medy Tox and AptaBio Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AptaBio Therapeutics are associated (or correlated) with Medy Tox. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medy Tox has no effect on the direction of AptaBio Therapeutics i.e., AptaBio Therapeutics and Medy Tox go up and down completely randomly.

Pair Corralation between AptaBio Therapeutics and Medy Tox

Assuming the 90 days trading horizon AptaBio Therapeutics is expected to under-perform the Medy Tox. In addition to that, AptaBio Therapeutics is 1.15 times more volatile than Medy Tox. It trades about -0.17 of its total potential returns per unit of risk. Medy Tox is currently generating about -0.16 per unit of volatility. If you would invest  18,864,100  in Medy Tox on September 2, 2024 and sell it today you would lose (5,724,100) from holding Medy Tox or give up 30.34% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

AptaBio Therapeutics  vs.  Medy Tox

AptaBio Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days AptaBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Medy Tox

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medy Tox has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with AptaBio Therapeutics and Medy Tox

The main advantage of trading using opposite AptaBio Therapeutics and Medy Tox positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AptaBio Therapeutics position performs unexpectedly, Medy Tox can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will offset losses from the drop in Medy Tox's long position.

The idea behind AptaBio Therapeutics and Medy Tox pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.